skip to Main Content
What Does a Plant Patent Covering the Charlotte’s Web Strain Mean for the CBD Industry?

By: Pauline M. Pelletier and Deborah A. Sterling, Ph.D.

Many cannabis and investor news outlets recently reported that the United States Patent & Trademark Office (USPTO) awarded what appears to be the first patent for a hemp strain to Denver-based Charlotte’s Web Holdings (CWBHF).[1] Plant patents are relatively rare compared to utility patents, but it will be important for those in the cannabis industry to understand their scope, how they compare and contrast to utility patents, and their potential impact on the cannabis industry.

CWBHF’s hemp strain patent, U.S. Plant Patent No. PP30,639, lists CEO Joel Stanley as an inventor and is directed to “a new and distinct hemp cultivar designated as ‘CW2A.’” The patent describes CW2A as a Cannabis sativa L. cultivar that is capable of producing up to 6.24% CBD and only 0.27% THC. The THC content of CW2A is notable for being below the 0.3% threshold required for federal classification as “hemp” under the 2018 Farm Bill. As background, the 2018 Farm Bill removed hemp from the scope of the Controlled Substances Act (CSA), opening the door for legal hemp cultivation in the United States.[2] CBD (cannabidiol) can be derived from hemp and has recently exploded in popularity. While regulators, including the US Food & Drug Administration (FDA), are still grappling with the rapidly-expanding CBD market, many in the cannabis industry are plowing forward with marketing plans in contemplation of federal regulations and state plan approvals that would authorize the legal cultivation of hemp.

Interest in hemp cultivation has risen in tandem with CBD’s popularity. According to a recent study by the Brightfield Group, 285,000 acres of hemp were planted in the United States in 2019, an increase of 72% from 2018, and as much as 87% of that hemp is expected to be used for CBD processing.[3] Indeed, CWBHF’s plant patent lists numerous potential market uses of the CW2A hemp strain, including: medical drugs, foods (e.g., margarine, food supplements), drinks (e.g., infused beverages, sports drinks), technical products (e.g., varnishes, fuel, print inks, solvents, coatings), personal hygiene products (e.g., cosmetics, soap, shampoo, bath gels), hemp-infused pet treats, textiles (e.g., apparel, diapers, fabrics, denim, socks, shoes, fine textiles, twine, rope, carpets, geotextiles), and building materials (e.g., fiber, insulation material, cement blocks). While some of these products (e.g., drugs, foods, drinks, pet treats) may require FDA approval, those not intended for human or animal consumption may not (e.g., textiles, building materials).

The issuance of CWBHF’s patent begs the question: what does this mean for those who make, use, or sell hemp that is capable of producing up to 6.24% CBD and only 0.27% THC? The answer is that plant patents are relatively narrow in scope. Plant patents, which were created by the Plant Patent Act of 1930, afford protection for asexually propagated plants (i.e., clones having identical genetics to those of the patented plant). Plant patents do not protect sexually produced plants (e.g., those cultivated by seed). As a result, a plant patent is infringed only when the infringer has cloned the accused plant from the plant protected by the patent. Plant patents are therefore generally not concerning to those who are seed farming or cultivating similar but not genetically identical plant varieties. If cloning proprietary strains ultimately proves critical to the cannabis industry, a patent covering such genetics could have far-reaching implications.

Utility patents, on the other hand, offer relatively broader protection and can be advantageous where the invention lies in the development of a plant or plant product that is cultivated to have previously unknown and non-naturally occurring properties. One advantage of utility patents over plant patents in this regard is that, if utility patent protection is awarded, the claimed invention can be infringed even if the accused product is reproduced sexually (e.g., by seed farming). Utility patents are routinely issued by the Patent Office for plants and plant elements (e.g., buds, pollen, fruit, plant-derived chemicals, extracts, proteins, engineered genes).

In sum, while a plant patent covering a commercially valuable strain for cloning purposes certainly has value, its scope is bounded to the genetics of the patented plant and leaves room for sexual reproduction (e.g., seed farming). By contrast, a utility patent covering a non-naturally occurring strain, where the claim is defined in terms of the plant’s novel characteristics could make the avoidance of infringement more difficult and thus serve as stronger patent protection.

Patents are a large investment and sophisticated strategies are needed to ensure that they provide value to their owners—whether for defensive purposes, offensive purposes, or both. And while patenting activity in the cannabis space has a history dating back to the 1950s, the recent growth in commercial value, investment interest, and biomedical innovation is proving to be a game-changer. As a result, the need for sophisticated patent counsel has never been greater.


[1] Chris Roberts, This is the first hemp strain to be awarded a US patent, Leafly (Sept. 13, 2019) (link); Graham Abbott, First U.S. Hemp Strain Patent Awarded for Charlotte’s Web, Ganjapreneur (Sept. 18, 2019) (link); Charlotte’s Web Holdings’ New Hemp Patent Could Be a Game Changer, Yahoo! Finance (Sept. 17, 2019) (link).

[2] For more information on the impact of the 2018 Farm Bill: IP’s Developing Role In Cannabis Business Strategy (link); Hemp Legalization and the International CBD Boom(link).

[3] Hemp Cultivation Surges Across US and Abroad, Brightfield Group (link).

Pauline Pelletier

Pauline Pelletier

Pauline M. Pelletier is a director in Sterne Kessler’s Trial & Appellate Practice Group. Pauline counsels clients in emerging and regulated industries, including cannabinoid therapeutics. [email protected], 202.772.8838

Deborah Sterling, Ph.D., is a director and chair of Sterne Kessler’s Biotechnology & Chemical Practice. Deborah counsels clients in emerging and regulated industries, including cannabinoid therapeutics. [email protected], 202.772.8501


This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Cannabis Legalization and its Impact on the Transportation Industry

Trends in Cannabis Legalization While employers in the transportation industry are acutely aware of the effects COVID-19 has imposed over the last 18 months, another phenomenon has been making itself known: the ever-increasing tally of states and localities across the country legalizing cannabis for medicinal and recreational purposes. A majority of states now have enacted…

German Police’s Move To Stop Adult-Use Cannabis Legalisation A Throwback To Dark Days Of Prohibition

CALLS by the leaders of two German police unions for politicians to U-Turn on the their progressive march towards cannabis legalisation have been roundly condemned. This comes as political talks continue towards the the formation of a cannabis-friendly ‘Traffic-Light Coalition’. It appears that it is just these talks – and the potential for adult-use legalisation…

N.J. announces 14 new medical marijuana licenses, expanding market after long delay

New Jersey has licensed 14 new marijuana businesses, bringing a long-awaited expansion of the state’s medical marijuana program that exceeds original plans. The Cannabis Regulatory Commission on Friday announced the winners of a competitive and burdensome licensing process that began two years ago. Nearly 200 entrepreneurs applied for licenses to grow and sell medical marijuana,…

Cannabis tech startup Dutchie raises $350M to double valuation to $3.75B in less than a year

Dutchie is rolling in the green. The Bend, Ore.-based creators of technology to help facilitate legal cannabis orders has raised $350 million in a Series D funding round, announced Thursday. The influx of new cash comes just seven months after the startup raised $200 million. Dutchie’s valuation has doubled to $3.75 billion. “Cannabis presents opportunities…

More Categories

Back To Top
×Close search